NEW YORK, October 10, 2016 /PRNewswire/ --
Pre-market, Stock-Callers.com shifts its focus on these four Biotechnology equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), Emergent BioSolutions Inc. (NYSE: EBS), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). In afternoon trading on Thursday, October 06, 2016, Biotech stocks were significantly weak, with the NYSE Arca Biotechnology Index down 3.1%. Learn more about these stocks by downloading their free report at:
Let us now see how the aforementioned companies fared at the closing bell the following day, Friday, October 07, 2016:
Pacific Biosciences of California
Last Friday, shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. ended the session 1.55% lower at $8.87. The stock recorded a trading volume of 684,924 shares. The Company's shares have advanced 1.60% in the last month and 18.11% in the previous three months. The stock is trading 2.67% above its 50-day moving average. Moreover, shares of Pacific Biosciences of California, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have a Relative Strength Index (RSI) of 52.37.
On September 22nd, 2016, Pacific Biosciences of California and Dovetail Genomics™ LLC announced that Dovetail has added PacBio® SMRT® sequencing and de novo assembly options to its menu of genome assembly services. The companies also announced their signing of a co-marketing agreement under which the new service offerings will be jointly promoted. The free research report on PACB is available at:
Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc.'s shares dropped 3.18%, to close the day at $1.52. The stock recorded a trading volume of 511,858 shares. The Company's shares have advanced 10.14% over the previous three months and are trading 9.03% below their 50-day moving average. Additionally, shares of Marinus Pharmaceuticals, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 43.20.
On September 29th, 2016, Marinus Pharmaceuticals announced top-line results from a Phase 2 exploratory open-label clinical trial evaluating ganaxolone, its CNS-selective GABAA modulator, in females with PCDH19 pediatric epilepsy. In the trial, ganaxolone reduced seizure frequency from baseline in the majority of patients enrolled in the study and was generally safe and well tolerated. PCDH19 pediatric epilepsy is a rare and serious epilepsy characterized by early-onset cluster seizures, cognitive and sensory impairment, and behavioral disturbances, with no approved treatments. In 2015, the U.S. Food and Drug Administration granted Orphan Drug Designation to ganaxolone for the treatment of PCDH19. The complimentary report on MRNS can be downloaded at:
Shares in Gaithersburg, Maryland headquartered Emergent BioSolutions Inc. recorded a trading volume of 702,667 shares at the close of the last trading session, which was above their three months average volume of 542,190 shares. The stock ended the day 2.23% lower at $31.19. The Company's shares have advanced 11.95% in the last one month and 2.36% in the previous three months. The stock is trading above its 50-day moving average by 9.26%. Furthermore, shares of Emergent BioSolutions, which develops, manufactures, and sells specialized products to healthcare providers and governments in the US and internationally, have an RSI of 62.04.
On September 30th, 2016, Emergent BioSolutions provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers for Disease Control and Prevention (CDC) for a follow-on procurement contract for BioThrax. The company stated that CDC has exercised an option to procure all remaining BioThrax doses, thereby committing to take delivery of the full 44.75 million doses, under the procurement contract announced on October 3rd, 2011 and due to expire September 30th, 2016. In concert with this option exercise, CDC has granted a no-cost extension to enable delivery of the remaining doses to be completed by November 30th, 2016. Visit us today and download our complete research report on EBS for free at:
Englewood, Colorado headquartered Ampio Pharmaceuticals Inc.'s stock finished Friday's session 1.82% higher at $0.80 with a total trading volume of 110,008 shares. Shares of the Company, which focuses on developing therapies for the treatment of prevalent inflammatory conditions in the US, are trading below their 50-day moving average by 8.90%. The stock has an RSI of 44.57.
On September 29th, 2016, Ampio Pharmaceuticals announced that the company has met with the CBER Division of the FDA to seek guidance on the best path forward to obtain a Biological License for Ampion™ to treat patients suffering from pain caused by severe osteoarthritis of the knee (OAK). Michael Macaluso, Ampio's CEO reported completion of enrollment for AP-011, a Study to Evaluate the Safety of a Single Intra-Articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint. Get free access to your technical report on AMPE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. RohitTuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA